Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Why Spur Therapeutics’ gene therapy data signals a shift in Gaucher disease bone management

New FLT201 data shows potential bone disease improvement in Gaucher patients. Find out what this means for future treatment strategies.

Read More
Representative image of a modern U.S. hospital and healthcare conference setting as Ardent Health heads to the Bank of America 2026 Healthcare Conference, where investors are expected to focus on ARDT stock sentiment, hospital margins, outpatient growth, and the company’s mid-sized urban healthcare strategy.
Pharma & Biotech

Why Ardent Health’s Bank of America fireside chat could matter for hospital sector sentiment

Hospital demand is resilient, but ARDT sentiment remains cautious. Ardent Health now has to prove margins can follow access growth.

Read More
Representative image of a modern pharmaceutical manufacturing facility, highlighting how Siegfried Holding AG’s acquisition of Noramco, Extractas Biosciences and Purisys could strengthen its position in complex API production, controlled-substance manufacturing and the global CDMO supply chain.
Pharma & Biotech

Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?

API security is becoming a CDMO battleground. Siegfried’s Noramco deal tests whether complex small molecules can drive the next growth phase.

Read More
Representative image of unbranded pharmaceutical packaging and medicine distribution inside a modern production setting, illustrating Knoa Pharma’s launch as a public health-focused successor to Purdue Pharma and the wider debate over opioid access, oversight, and opioid crisis abatement.
Pharma & Biotech

Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?

Purdue is gone, but its medicines remain. Knoa Pharma’s public health model now faces its hardest test: trust, access, and oversight.

Read More
Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.
Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More
Representative image of advanced autoimmune drug research, reflecting UCB’s proposed acquisition of Candid Therapeutics and the rising focus on T-cell engager therapies.
Pharma & Biotech

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Read More
Representative image of a weekly contraceptive patch being assessed in a clinical setting, reflecting Viatris Inc.’s MR-100A-01 data update as the FDA review places low-dose estrogen transdermal contraception back in focus.
Pharma & Biotech

Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?

Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.

Read More
Representative image: An ophthalmology clinic scene showing retinal imaging and eye examination technology, reflecting Kodiak Sciences’ KSI-101 clinical data in macular edema secondary to inflammation and the growing role of biologics in inflammatory retinal disease treatment.
Pharma & Biotech

Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?

Steroids still dominate MESI care. Kodiak’s KSI-101 may test whether local biologics can change inflammatory retina treatment.

Read More
Representative image: A ferry passenger experiencing motion sickness, reflecting Vanda Pharmaceuticals Inc.’s U.S. launch of NEREUS as a new prescription treatment option for adults with vomiting induced by motion.
Pharma & Biotech

Can direct to consumer access help Vanda scale NEREUS beyond niche travel use?

Motion sickness finally has a new prescription drug. Vanda’s test is whether NEREUS can move beyond travel novelty into real demand.

Read More
Representative image: Pediatric endocrine care is drawing renewed attention as Neurocrine Biosciences’ CRENESSITY two-year CAHtalyst Pediatric data show durable hormone control, reduced glucocorticoid exposure and potential long-term clinical benefits for children with classic congenital adrenal hyperplasia.
Pharma & Biotech

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Read More